By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Epigenomics today said that its full-year 2009 revenues increased 65 percent as the firm entered into its commercial phase through the launch of colorectal cancer tests.

The German molecular diagnostics firm reported full-year revenues of €4.3 million ($5.8 million), up 65 percent from €2.6 million for FY 2008.

Its loss before interest and tax was €10.2 million versus a loss of €12.8 million for 2008.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Penn State Hershey Medical Center staffer has admitted to lying about skipping mandatory steps of genetic cancer tests he performed, the Associated Press reports.

The genome of a rare, red bat suggests that its effective population size has been in decline for thousands of years, according to a PLOS One study.

In Nature this week: investigation into the genetics of medulloblastoma, and more.

A project in the UK is to use genomic selection to speed spruce tree growth, according to Innovators Magazine.